Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | POLD1 | P28340 | 1/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | TK1 | P04183 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14596612 | 1.00 | POLB (0.61) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL29636240 | 0.97 | POLB (0.60) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL14627710 | 0.97 | POLB (0.60) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL30719004 | 0.95 | POLB (0.59) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL14596600 | 0.95 | POLB (0.59) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL30349103 | 0.95 | POLB (0.60) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL25574747 | 0.90 | POLB (0.59) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL15948703 | 0.85 | POLB (0.64) | POLBPOLA1POLD1ABCG2ABCB1 | |
| SCHEMBL14596610 | 0.84 | BCHE (0.42) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL14596602 | 0.84 | BCHE (0.42) | POLBPOLA1POLD1TK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | TYMP, PNP, APRT | POLB 491/4885POLA1 1129/4885POLD1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.